Technical Analysis for PRLD - Prelude Therapeutics Incorporated
Grade | Last Price | % Change | Price Change |
---|---|---|---|
F | 0.96 | 0.17% | 0.00 |
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Very Strong | Down | Down | Down |
Date | Alert Name | Type | % Chg |
---|---|---|---|
Boomer Sell Setup | Bearish Swing Setup | 0.00% | |
NR7 | Range Contraction | 0.00% | |
Narrow Range Bar | Range Contraction | 0.00% | |
Inside Day | Range Contraction | 0.00% | |
Wide Bands | Range Expansion | 0.00% | |
Oversold Stochastic | Weakness | 0.00% | |
Narrow Range Bar | Range Contraction | 0.17% | |
Inside Day | Range Contraction | 0.17% | |
Wide Bands | Range Expansion | 0.17% | |
Oversold Stochastic | Weakness | 0.17% |
Alert | Time |
---|---|
Possible NR7 | about 17 hours ago |
Possible Inside Day | about 17 hours ago |
Up 3% | about 22 hours ago |
Up 2% | about 22 hours ago |
Up 1% | about 22 hours ago |
Free Daily (Stock) Chart Reading
- Earnings date: 10/30/2024
Prelude Therapeutics Incorporated Description
Prelude Therapeutics Incorporated, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule therapies optimized to target the key driver mechanisms in cancers. It is developing PRT543 that is in Phase 1 clinical trials in select solid tumors and myeloid malignancies in patients who are refractory to or intolerant of established therapies; and PRT811, which is in Phase 1 clinical trials in solid tumors, including glioblastoma multiforme and primary central nervous system lymphomas. The company is also developing PRT1419, a potent and selective inhibitor of the anti-apoptotic protein; PRT2527, a potent inhibitor of CDK9 that exhibits high kinome selectivity; PRT-SCA2 for multiple genomically selected cancers; and PRT-K4 for solid tumors. Prelude Therapeutics Incorporated was founded in 2016 and is based in Wilmington, Delaware.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Cancer Solid Tumors Lymphoma Blastoma Glioblastoma Protein Kinase Inhibitor Tyrosine Kinase Receptors Small Molecule Therapies Glioblastoma Multiforme Phosphoinositide 3 Kinase Inhibitor
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 6.8 |
52 Week Low | 0.931 |
Average Volume | 385,203 |
200-Day Moving Average | 3.80 |
50-Day Moving Average | 1.80 |
20-Day Moving Average | 1.22 |
10-Day Moving Average | 1.08 |
Average True Range | 0.12 |
RSI (14) | 21.26 |
ADX | 61.5 |
+DI | 6.09 |
-DI | 37.89 |
Chandelier Exit (Long, 3 ATRs) | 1.43 |
Chandelier Exit (Short, 3 ATRs) | 1.30 |
Upper Bollinger Bands | 1.58 |
Lower Bollinger Band | 0.85 |
Percent B (%b) | 0.15 |
BandWidth | 59.74 |
MACD Line | -0.29 |
MACD Signal Line | -0.31 |
MACD Histogram | 0.0269 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 1.02 | ||||
Resistance 3 (R3) | 1.02 | 1.01 | 1.01 | ||
Resistance 2 (R2) | 1.01 | 0.99 | 1.01 | 1.01 | |
Resistance 1 (R1) | 0.98 | 0.98 | 1.00 | 0.98 | 1.01 |
Pivot Point | 0.97 | 0.97 | 0.97 | 0.97 | 0.97 |
Support 1 (S1) | 0.94 | 0.95 | 0.96 | 0.94 | 0.92 |
Support 2 (S2) | 0.93 | 0.94 | 0.93 | 0.92 | |
Support 3 (S3) | 0.90 | 0.93 | 0.91 | ||
Support 4 (S4) | 0.90 |